| Biocept is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid. Co. has commercialized its CNSide and Target Selector assays for detecting and characterizing various different carcinomas derived from epithelial cells of solid organs such as: breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. In addition, Co. has launched RT-PCR Coronavirus testing at its laboratory. The BIOC average annual return since 2014 is shown above.
The Average Annual Return on the BIOC average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BIOC average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BIOC average annual return calculation with any dividends reinvested as applicable (on ex-dates).